PSMA-based 18F-DCFPyL PET: a better choice than multiparametric MRI for prostate cancer diagnosis?

Xiao Zhang; Mai Hong Son; Le Ngoc Ha; Xiaoli Lan

PSMA-based ¹⁸F-DCFPyL PET: a better choice than multiparametric MRI for prostate cancer diagnosis?

Am J Nucl Med Mol Imaging. 2022 Dec 15;12(6):195-200. eCollection 2022.

Authors

Xiao Zhang^{1

2}, Mai Hong Son³, Le Ngoc Ha³, Xiaoli Lan^{1

2}

Affiliations

¹ Department of Nuclear Medicine, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology Wuhan 430022, Hubei, China.
² Hubei Key Laboratory of Molecular Imaging Wuhan 430022, Hubei, China.
³ Department of Nuclear Medicine, Hospital 108 Hanoi, Vietnam.

PMID: 36636231
PMCID: PMC9831858

Abstract

Owing to the high tissue contrast, multiparametric MRI (mpMRI) has already been the most widely applied imaging method for prostate cancer. Recently, prostate-specific membrane antigen (PSMA) ligands for nuclear imaging are emerging as a promising modality in prostate cancer, especially since the 2 PET/CT agents (⁶⁸Ga-PSMA-11 and ¹⁸F-DCFPy) approved by U.S. Food and Drug Administration (FDA). However, limited studies have performed the comparison of mpMRI versus recently approved ¹⁸F-DCFPyL PET/CT. In this issue of AJNMMI, Lu et al. compared the performance of ¹⁸F-DCFPyL PET/CT and pelvic mpMRI in intermediate-high risk and biochemical recurrent prostate cancer patients. The results demonstrated the two modalities have a good concordance rate for patient-based analysis, and ¹⁸F-DCFPyL PET/CT has a better diagnostic performance in detecting lymph node metastases and bone metastases for lesion-based analysis. The use of ¹⁸F-DCFPyL PET/CT provides more diagnostic confidence to better assess prostate cancer lesions.

Keywords: 18F-DCFPyL; 68Ga-PSMA-11; PET; PSMA; multiparametric MRI.

Publication types

Editorial